TyRx Pharma, Inc. has recently been granted USFDA 510(k) clearance for PIVIT™ AB, a new surgical mesh product coated with a proprietary bioresorbable polymer containing the antimicrobial agents: rifampin and minocycline.

PIVIT™ AB, indicated for the repair of hernias and other abdominal fascial deficiencies (requiring the addition of a reinforcing or bridging material to obtain the desired surgical result) is expected to be launched by TyRx during the 3rd quarter of this year (2006).

PIVIT™ AB's antimicrobial coating is designed to help provide protection from microbial colonization of the device during surgical implantation.

PIVIT™ is TyRx's 1st bioresorbable polymer coated surgical mesh product whose unique properties give the surgical mesh good handling characteristics that facilitate precise placement during the surgical repair and leaves less implant material following the resorption of the bioresorbable polymer coating.

Read more at TyRx Pharma, Inc.